⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2570729 | 0.72 | — | — | |
| SCHEMBL51846 | 0.72 | — | — | |
| SCHEMBL1497948 | 0.72 | — | — | |
| SCHEMBL9235021 | 0.68 | — | — | |
| SCHEMBL95260 | 0.67 | — | — | |
| SCHEMBL1661429 | 0.65 | — | — | |
| SCHEMBL1669550 | 0.65 | — | — | |
| SCHEMBL22616780 | 0.65 | — | — | |
| SCHEMBL11583637 | 0.62 | — | — | |
| SCHEMBL10788720 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109988842-B | Reagent group for in-situ detection of PDL1 by oligonucleotide labeled probe and application thereof | 上海吉玛制药技术有限公司 | 2022-12-06 | — | — | CN | claimed |
| US-20240000767-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2024-01-04 | — | — | US | disclosed |
| WO-2023131640-A1 | α2-ADRENOCEPTOR SUBTYPE C ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023118122-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A P2X3 RECEPTOR ANTAGONIST FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023118102-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A MUSCARINIC RECEPTOR ANTAGONIST FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023118126-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | WO | disclosed |
| EP-4175954-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2023-05-10 | — | — | EP | disclosed |
| CN-116057057-A | Conjugates of alpha 2-adrenoceptor subtype C (alpha-2C) antagonists and TASK1/3 channel blockers for the treatment of sleep apnea | 拜耳公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-109988842-B | Reagent group for in-situ detection of PDL1 by oligonucleotide labeled probe and application thereof | 上海吉玛制药技术有限公司 | 2022-12-06 | — | — | CN | disclosed |
| US-20220218700-A1 | COMBINATION OF AN ?2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2022-07-14 | — | — | US | disclosed |
| EP-1910325-B1 | NEW PHARMACEUTICAL COMPOUNDS | ORION CORP (FI) | 2010-10-06 | — | — | EP | disclosed |
| US-20100216836-A1 | 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES | ORION CORPORATION (FI) | 2010-08-26 | — | — | US | disclosed |
| WO-2010058060-A1 | ARYL PIPERAZINE AND THEIR USE AS ALPHA2C ANTAGONISTS | ORION CORPORATION (FI) | 2010-05-27 | — | — | WO | disclosed |
| EP-2176252-A1 | 2, 3-DIHYDROBENZO[1, 4]DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES | ORION CORPORATION (FI) | 2010-04-21 | — | — | EP | disclosed |
| US-20090209532-A1 | PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2009-08-20 | — | — | US | disclosed |
| WO-2009013390-A1 | 2, 3-DIHYDROBENZO[1, 4] DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES | ORION CORPORATION (FI) | 2009-01-29 | — | — | WO | disclosed |
| EP-1910325-A2 | NEW PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007010085-A2 | NEW PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2007-01-25 | — | — | WO | disclosed |
| CN-1087694-C | Recording media | TOYO BOSEKI (JP) | 2002-07-17 | — | — | CN | disclosed |
| CN-1174129-A | Recording media | TOYO BOSEKI (JP) | 1998-02-25 | — | — | CN | disclosed |